Merck & Co., Inc. (NYSE:MRK) Receives Average Rating of “Moderate Buy” from Analysts

Merck & Co., Inc. (NYSE:MRK) has been assigned a consensus rating of “Moderate Buy” from the nineteen research firms that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $128.1765.

A number of research firms have weighed in on MRK. UBS Group increased their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Cantor Fitzgerald upped their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. TD Cowen increased their price target on Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a report on Tuesday, January 20th. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $111.26 on Friday. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The stock has a market capitalization of $274.78 billion, a price-to-earnings ratio of 31.34, a PEG ratio of 2.53 and a beta of 0.18. The company has a 50-day simple moving average of $117.07 and a 200-day simple moving average of $108.31. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.30 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts predict that Merck & Co., Inc. will post 5.16 EPS for the current year.

Insider Activity

In related news, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president directly owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CMO Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the completion of the sale, the chief marketing officer owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is owned by insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Large investors have recently modified their holdings of the business. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. during the fourth quarter worth $25,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $26,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $26,000. IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $31,000. Finally, High Note Wealth LLC boosted its position in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.